Clinical trials: Flu Vaccination
Influenza Caused by the Novel Influenza A (H1N1) Virus
A Clinical Trial of CSL's 2009 H1N1 Influenza Vaccine (CSL425) in Healthy Children
The purpose of this study is to determine whether CSL425 is a safe and effective vaccine for eliciting an immune response to H1N1 influenza in healthy children.
- Trial name
- NCT00940108
- Testing
- CSL425
- Where
- 5 sites in Australia
- Volunteers
- 370 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults
A Phase 2b Study to Determine the Efficacy of Candidate Influenza Vaccine MVA-NP+M1 in Adults aged 18 years and over. To assess the effect of MVA-NP+M1 on the reduction of laboratory confirmed influenza when given as an adjunct…
- Trial name
- NCT03880474
- Testing
- MVA-NP+M1, Saline
- Where
- 9 sites in Australia
- Volunteers
- 2,364 people, healthy volunteers welcome
- Sponsor
- Barinthus Biotherapeutics
Influenza Virus
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to <72 Months of Age.
- Trial name
- NCT01964989
- Testing
- Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
- Where
- 167 sites in United States, Canada and 9 more
- Volunteers
- 10,644 people, healthy volunteers welcome
- Sponsor
- Seqirus
Seasonal Influenza
Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers
The present study will evaluate the safety in healthy people aged 1- 45 years (male and female) after single intramuscular (IM) dose of trivalent subunit inactivated influenza vaccine till the 30-days follow-up period.
- Trial name
- NCT01123954
- Testing
- Seasonal flu vaccine
- Where
- Vietnam
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza Immunization
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
The purpose of this study was to demonstrate the non-inferiority (NI) of the HAI immune response of RIV4 in participants aged 9 to 17 years vs participants aged 18 to 49 years and to describe the immunogenicity and safety profile…
- Trial name
- NCT05513053
- Testing
- Quadrivalent Recombinant influenza vaccine (RIV4) season/2022-2023/NH
- Where
- 35 sites in United States, Czechia and 2 more
- Volunteers
- 1,308 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008
Due to antigenic changes of influenza viruses, the virus strains used in influenza vaccines are adjusted every year according to WHO and CPMP recommendations.
- Trial name
- NCT00518453
- Testing
- Surface antigen inactivated influenza vaccine
- Where
- United Kingdom
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age.
- Trial name
- NCT00976820
- Testing
- GSK2340274A, GSK2340273A
- Where
- 30 sites in United States, Canada
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immune Response Following Seasonal Influenza Vaccination
This is an open-label, single administration dose study in adult healthy male and female subjects. After qualifying for the study, subjects will receive a single intramuscular injection of the FDA approved 2016-2017 quadrivalent…
- Trial name
- NCT03163342
- Testing
- Licensed seasonal influenza vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Influenza
Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES Databases
In 2013, the NHS started a vaccination program in some regions of England to provide free flu vaccines to children aged 2 years or older, and younger than 16 years. The program has since been rolled out across England.
- Trial name
- INOCULATE (NCT06077045)
- Where
- United Kingdom
- Volunteers
- 12,775,880 people
- Sponsor
- AstraZeneca
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults
This study is designed to test the immunogenicity in terms of Hemagglutination Inhibition (HI) antibodies against each of the three vaccine influenza strains and reactogenicity and safety of Fluviral® containing the influenza…
- Trial name
- NCT01626820
- Testing
- Fluviral®
- Where
- Canada
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Immunisation, Healthy Volunteers
Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects
The primary objectives of the study are: To describe the safety profile of the different formulations in all participants To describe the hemagglutinin inhibition (HAI) and seroneutralization (SN) antibody responses against…
- Trial name
- FBP00004 (NCT04451954)
- Testing
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2
- Where
- 5 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pandemic Influenza Disease
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects
The present study aims to evaluate safety and immunogenicity of two doses, administered three weeks apart, of two influenza vaccines containing 7.5 micrograms or 15 micrograms of H5N1 influenza antigen, in non-elderly adult and…
- Trial name
- NCT00311480
- Testing
- Influenza vaccine surface antigen adjuvanted with MF59
- Where
- 4 sites in Italy
- Volunteers
- 520 people
- Sponsor
- Novartis
Influenza
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years…
- Trial name
- NCT00521586
- Testing
- 13 valent pneumococcal conjugate vaccine
- Where
- 41 sites in United States
- Volunteers
- 1,116 people, healthy volunteers welcome
- Sponsor
- Pfizer
Vaccine Response
Probiotics and Influenza Vaccination Response
Assess efficacy of oral ingestion of a probiotic product on immune function in a population of healthy adult men and women in a clinical vaccination study.
- Trial name
- VERB (NCT05690373)
- Testing
- Probiotic effect on influenza vaccine response
- Where
- Netherlands
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company